Octreotide fluid crystal provides sustained octreotide bioavailability and similar IGF1 suppression to that of octreotide LAR (Sandostatin LAR): randomized, open-label, Phase I, repeat-dose study in healthy volunteers

Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | ISSN 1479-6848 (online)